Esther Porras-De Francisco
Overview
Explore the profile of Esther Porras-De Francisco including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
160
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Flipo M, Frita R, Bourotte M, Martinez-Martinez M, Boesche M, Boyle G, et al.
Sci Transl Med
. 2022 May;
14(643):eaaz6280.
PMID: 35507672
The sensitivity of , the pathogen that causes tuberculosis (TB), to antibiotic prodrugs is dependent on the efficacy of the activation process that transforms the prodrugs into their active antibacterial...
2.
Gold B, Zhang J, Lopez Quezada L, Roberts J, Ling Y, Wood M, et al.
ACS Infect Dis
. 2022 Feb;
8(3):557-573.
PMID: 35192346
Rising antimicrobial resistance challenges our ability to combat bacterial infections. The problem is acute for tuberculosis (TB), the leading cause of death from infection before COVID-19. Here, we developed a...
3.
Moure A, Narula G, Sorrentino F, Bojang A, Tsui C, Emani C, et al.
J Med Chem
. 2020 Apr;
63(9):4732-4748.
PMID: 32275415
Screening of a GSK-proprietary library against intracellular identified , a thioalkylbenzoxazole hit. Biological profiling and mutant analysis revealed that this compound is a prodrug that is bioactivated by the mycobacterial...
4.
Dutta N, Klinkenberg L, Vazquez M, Segura-Carro D, Colmenarejo G, Ramon F, et al.
Sci Adv
. 2019 Mar;
5(3):eaav2104.
PMID: 30906866
The stringent response enables () to shut down its replication and metabolism under various stresses. Here we show that lacking the stringent response enzyme Rel was unable to slow its...
5.
Guardia A, Baiget J, Cacho M, Perez A, Ortega-Guerra M, Nxumalo W, et al.
J Med Chem
. 2018 Nov;
61(24):11327-11340.
PMID: 30457865
Society urgently needs new, effective medicines for the treatment of tuberculosis. To kick-start the required hit-to-lead campaigns, the libraries of pharmaceutical companies have recently been evaluated for starting points. The...
6.
Warrier T, Martinez-Hoyos M, Marin-Amieva M, Colmenarejo G, Porras-De Francisco E, Alvarez-Pedraglio A, et al.
ACS Infect Dis
. 2016 Sep;
1(12):580-5.
PMID: 27623055
Identification of compounds that target metabolically diverse subpopulations of Mycobacterium tuberculosis (Mtb) may contribute to shortening the course of treatment for tuberculosis. This study screened 270,000 compounds from GlaxoSmithKline's collection...
7.
Warrier T, Kapilashrami K, Argyrou A, Ioerger T, Little D, Murphy K, et al.
Proc Natl Acad Sci U S A
. 2016 Jul;
113(31):E4523-30.
PMID: 27432954
The rising incidence of antimicrobial resistance (AMR) makes it imperative to understand the underlying mechanisms. Mycobacterium tuberculosis (Mtb) is the single leading cause of death from a bacterial pathogen and...